Medication info
Empagliflozin/Metformin Duo Tablet 5/1000 mg (Empagliflozin, Metformin Hydrochloride)

Empagliflozin/Metformin Duo Tablet 5/1000 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Pamgen Science Co., Ltd.
Appearance
Yellow oval film-coated tablet with a brownish hue, biconvex on both sides
Packaging
10 tablets/box [(10 tablets/PTP x 1)], 60 tablets/box [(10 tablets/PTP x 6)], 60 tablets/bottle, 30 tablets/bottle
Approval status
Active

MFDS item code 202201345 · Approved 2022.04.04 · Insurance code 670105330

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their previous doses of empagliflozin and metformin. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose, take it as soon as you remember. However, do not take twice the dose at one time; in this case, skip the missed dose. Special Populations Patients with Renal Impairment No dose adjustment is required for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who have no other condition that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily, so treatment should be initiated with the individual single-ingredient products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately (see Precautions for Use, 2. Do not administer to the following patients, item 2)). Elderly Patients In patients aged 75 years or older, consider renal function and the risk of volume depletion.

Ingredients

Manufacturer
Pamgen Science Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes with difficulty in blood sugar control
  • cardiovascular disease
View approved original text

This medication is used to assist in blood sugar control for adult patients with type 2 diabetes who find it difficult to manage blood sugar levels through diet and exercise alone. It can also be administered to patients with a history of cardiovascular disease; however, in such cases, a specialist's guidance must be followed. Empagliflozin and Metformin work together to effectively improve blood sugar levels.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their previous doses of empagliflozin and metformin. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose, take it as soon as you remember. However, do not take twice the dose at one time; in this case, skip the missed dose. Special Populations Patients with Renal Impairment No dose adjustment is required for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who have no other condition that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily, so treatment should be initiated with the individual single-ingredient products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately (see Precautions for Use, 2. Do not administer to the following patients, item 2)). Elderly Patients In patients aged 75 years or older, consider renal function and the risk of volume depletion.

Precautions

This medication is utilized for the treatment of type 2 diabetes and aids in blood sugar regulation. One of the main components of this medication is Metformin, which is excreted by the kidneys and should not be administered to patients with impaired kidney function. Additionally, Metformin can cause a rare side effect known as lactic acidosis, which can be life-threatening, so caution is necessary. During the administration of this medication, hypoglycemic symptoms may occur if used with insulin or sulfonylurea medications, and extra vigilance is required. Patients with moderate to severe renal impairment, those at risk for acute kidney injury, or patients with unstable health conditions such as severe infection, dehydration, or heart failure should not take this medication. Administration of this medication should be temporarily halted before and after using iodinated contrast agents, and can only be resumed after kidney function has recovered to normal. It is recommended that pregnant or breastfeeding women avoid this medication for safety. This medication may lead to fluid loss, especially in elderly patients or those with low blood pressure; therefore, caution is necessary during use. There may be an increased risk of urinary and genital infections, so individuals should consult healthcare professionals immediately if related symptoms occur. Vitamin B12 deficiency may occur; hence, regular monitoring of Vitamin B12 levels is advisable for prolonged use. Alcohol consumption should preferably be avoided while taking this medication, as excessive drinking may increase the risk of lactic acidosis. Hypoglycemic symptoms may emerge, so particular caution should be taken if meals are skipped or irregular. For patients scheduled for surgery, this medication should be discontinued 48 hours prior to the procedure and can be resumed after kidney function normalizes post-surgery. This medication is not recommended for children under the age of 18, as safety and efficacy have not been established. In case of overdose, serious side effects such as lactic acidosis may occur, thus it should be taken strictly according to the physician's instructions. This medication should be kept out of reach of children and should be stored in its original container.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
Show 167 more
  • abnormal liver function tests
  • hepatitis
  • abnormal taste
  • itching
  • rash
  • urticaria
  • erythema multiforme
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • ketoacidosis
  • lactic acidosis
  • decreased fluid volume
  • fluid loss
  • low blood pressure
  • hypotension
  • decreased blood volume
  • orthostatic hypotension
  • syncope
  • vulvovaginitis
  • balanitis
  • perineal necrosis
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • lower gastrointestinal bleeding
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • sepsis
  • subcutaneous abscess
  • tubo-ovarian abscess
  • vestibular neuritis
  • headache
  • sensory impairment
  • positional dizziness
  • dizziness
  • drowsiness
  • weakness
  • chest discomfort
  • chest pain
  • fever
  • facial swelling
  • chills
  • strange feeling
  • edema
  • pain
  • pain at the puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • weight loss
  • vulvar pruritus
  • benign prostatic hyperplasia
  • diabetic retinopathy
  • diplopia
  • hypertension
  • insomnia
  • constipation
  • nasopharyngitis
  • herpes zoster
  • glaucoma
  • pathological myopia
  • retinal detachment
  • retinal vein occlusion
  • macular detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • cough
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina pectoris
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral artery occlusive disease
  • anxiety
  • depression
  • sleep disturbances
  • ear pain
  • positional vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • circular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • macular fibrosis
  • ocular discomfort
  • eye congestion
  • diabetic neuropathy
  • facial paralysis
  • intracranial aneurysm
  • memory impairment
  • neuralgia
  • Parkinsonism
  • polyneuropathy
  • sensory disturbances
  • drowsiness
  • CNS-origin vertigo
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture; therefore, it should be stored in a tightly closed container. It is important to maintain a storage temperature between 1 and 30 degrees Celsius. This will help preserve the effectiveness and safety of the medication for a longer period.

Appearance and packaging

Appearance

Yellow oval film-coated tablet with a brownish hue, biconvex on both sides

Package unit

10 tablets/box [(10 tablets/PTP x 1)], 60 tablets/box [(10 tablets/PTP x 6)], 60 tablets/bottle, 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.